Nevertheless, the observed synergy between D20 and Y45, which reduces the Treg population while increasing CD8+ T cells, particularly in the central memory T cell (Tcm) stage, characterized by self‐renewal potential and the capacity to differentiate into effector T cells, offers a promising strategy for developing more effective and selective IL‐2‐based cancer immunotherapies. This evidence concerns the gene CD8A and cancer.